Effects of the Combination of Atomoxetine and Oxybutynin on OSA Endotypic Traits

BACKGROUND: We recently showed that administration of the combination of the noradrenergic drug atomoxetine plus the antimuscarinic oxybutynin (ato-oxy) prior to sleep greatly reduced OSA severity, likely by increasing upper airway dilator muscle activity during sleep. In patients with OSA who perfo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Chest
Autors principals: Taranto-Montemurro, Luigi, Messineo, Ludovico, Azarbarzin, Ali, Vena, Daniel, Hess, Lauren B., Calianese, Nicole A., White, David P., Wellman, Andrew, Sands, Scott A.
Format: Artigo
Idioma:Inglês
Publicat: American College of Chest Physicians 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7268440/
https://ncbi.nlm.nih.gov/pubmed/32006590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2020.01.012
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars